Find disease awareness content and relevant supporting materials

The UK's National Institute for Health and Care Excellence (NICE) has recommended Opdivo (nivolumab), from Bristol Myers Squibb, as a treatment for certain resected oesophageal or gastro-oesophageal junction (GEJ) patients.

Bristol Myers Squibb announced that checkpoint inhibitor treatment Opdivo (nivolumab) demonstrated its efficacy in the phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction cancers who had previously received neoadjuvant chemoradiation therapy and tumour resection.

Recently, long noncoding RNA (lncRNA) have been shown to have a role in cancer initiation and progression and have also been studied in thyroid cancer.

Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).

NICE (UK);Trifluridine–tipiracil (Lonsurf) is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.

Press release from ESMO 2017

Ono Pharmaceutical Co. Ltd.announced that Opdivo (nivolumab) met the primary endpoint vs. chemotherapy of improving overall survival in the Phase...

Background: Current guidance on the management of sepsis often applies to infection originating from abdominal or pelvic sources, which presents specific challenges and opportunities for efficient and rapid source control.

The field of research in bladder cancer has seen significant advances in recent years. Next-generation sequencing has identified the genes most mutated in bladder cancer.

Analyze the relationship between blood lipid levels and ovarian cancer risk, focusing on the findings from a systematic review and meta-analysis of observational epidemiologic studies.